DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for arteriosclerosis — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleArteriosclerosis maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for arteriosclerosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phospholipase A2 group VII (PLA2G7) — PLA2G7 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3F97 · 1.7 Å · ligand (1R)-1,2,2-TRIMETHYLPROPYL (R)-METHYLPHOSPHINATE (GD7). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1957 · 8 citations
Choice of Therapy for Peripheral Arteriosclerosis
AbstractAS surgical methods become available in the management of peripheral arteriosclerosis, the proper choice of treatment, for a particular problem encountered, becomes important. Such a choice necessitates an accurate appraisal of the pathology in the individual patient, and a knowledge of the results to be expected from various methods of treatment.Major surgery is justified only if life expectancy is adequate. The latest figures for the general population above forty years of age are impressively high (Table 1). How the general expectancy is affected by the presence of peripheral arteriosclerosis is not well documented. A study of 100 patients after . . .
American Journal of Clinical Pathology · 1938 · 2 citations · open access
The Biology of Arteriosclerosis
AbstractThe Biology of Arteriosclerosis Get access The Biology of Arteriosclerosis. By M. C. Winternitz, M.D., R. M. Thomas, M.D., and P. M. le Compte, M.D. Cloth, 142 pp., 60 figures, in black and white and 56 colored plates, $4.00. Charles C. Thomas, Springfield, Ill. American Journal of Clinical Pathology, Volume 8, Issue 6, 1 November 1938, Pages 658–659, https://doi.org/10.1093/ajcp/8.6.658b Published: 12 November 2015
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
